Natasha Hernday
Director/Board Member at ALPINE IMMUNE SCIENCES, INC.
Net worth: - $ as of 2024-03-30
Natasha Hernday active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | 2010-12-31 | - |
| XOMA CORPORATION | Director/Board Member | 2020-06-29 | - |
| Independent Dir/Board Member | 2020-06-29 | - | |
| ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 2020-12-09 | - |
| Independent Dir/Board Member | 2020-12-09 | - |
Career history of Natasha Hernday
Former positions of Natasha Hernday
| Companies | Position | Start | End |
|---|---|---|---|
| PDL BIOPHARMA, INC. | Director/Board Member | 2019-06-23 | 2022-11-30 |
| Independent Dir/Board Member | 2019-06-23 | 2022-11-30 | |
| AMGEN INC. | Corporate Officer/Principal | 1994-06-30 | 2009-12-31 |
Training of Natasha Hernday
| Pepperdine University | Masters Business Admin |
| University of California, Santa Barbara | Undergraduate Degree |
Statistics
International
| United States | 8 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| XOMA CORPORATION | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Stock Market
- Insiders
- Natasha Hernday
- Experience
